首页 > 最新文献

Diabetes research and clinical practice最新文献

英文 中文
Extracorporeal shock wave therapy (ESWT) favors healing of diabetic foot ulcers: A systematic review and meta-analysis 体外冲击波疗法(ESWT)有利于糖尿病足溃疡的愈合:系统回顾和荟萃分析。
IF 6.1 3区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-09-03 DOI: 10.1016/j.diabres.2024.111843

Aims

To investigate the efficacy and safety of extracorporeal shockwave therapy(ESWT) for diabetic foot ulcers(DFUs).

Methods

Search in PubMed, EMBASE, the Cochrane Controlled Register of Trials (CENTAL), and Web of Science for randomized controlled trials (RCTs) published before August 8, 2023. All identified studies were screened following the selection criteria. Finally, we employed the STATA 14.0 software for conducting a meta-analysis to evaluate the efficacy and safety of ESWT.

Results

A total of ten RCTs with moderate methodological quality were included for data analysis. The findings showed that ESWT was significantly associated with significantly complete healed ulcers (risk ratio [RR]: 1.57, 95 % confidence interval [CI]:1.26 to 1.95) and lower rate of unchanged ulcers (RR: 0.25, 95 %CI: 0.14 to 0.42) compared to controls. Subgroup analysis further revealed that ESWT was better than both hyperbaric oxygen therapy (HOT) and the standard of care (SOC). Moreover, ESWT also significantly improved the average transcutaneous partial oxygen pressure (TcPO2) (mean difference[MD]: 1.71, 95 %CI: 1.22 to 2.19, p < 0.001). However, the rate of ≥ 50 % improved ulcers and treatment-emergent adverse events (TEAEs) were not significantly different between the ESWT and controls.

Conclusions

ESWT has shown promising efficacy and a favorable safety profile in the treatment of DFUs.

目的:研究体外冲击波疗法(ESWT)治疗糖尿病足溃疡(DFUs)的有效性和安全性:在PubMed、EMBASE、Cochrane对照试验登记(CENTAL)和Web of Science中搜索2023年8月8日之前发表的随机对照试验(RCT)。我们按照筛选标准对所有确定的研究进行了筛选。最后,我们使用 STATA 14.0 软件进行了荟萃分析,以评估 ESWT 的有效性和安全性:结果:我们共纳入了 10 项方法学质量中等的 RCT 进行数据分析。结果显示,与对照组相比,ESWT 与溃疡明显完全愈合(风险比 [RR]:1.57,95% 置信区间 [CI]:1.26 至 1.95)和溃疡未愈合率较低(RR:0.25,95%CI:0.14 至 0.42)有显著相关性。分组分析进一步显示,ESWT 的效果优于高压氧疗法(HOT)和标准护理(SOC)。此外,ESWT 还能明显改善平均经皮氧分压(TcPO2)(平均差[MD]:1.71, 95 %CI: 1.22 to 2.19, p 结论:ESWT 在治疗 DFU 方面具有良好的疗效和安全性。
{"title":"Extracorporeal shock wave therapy (ESWT) favors healing of diabetic foot ulcers: A systematic review and meta-analysis","authors":"","doi":"10.1016/j.diabres.2024.111843","DOIUrl":"10.1016/j.diabres.2024.111843","url":null,"abstract":"<div><h3>Aims</h3><p>To investigate the efficacy and safety of extracorporeal shockwave therapy(ESWT) for diabetic foot ulcers(DFUs).</p></div><div><h3>Methods</h3><p>Search in PubMed, EMBASE, the Cochrane Controlled Register of Trials (CENTAL), and Web of Science for randomized controlled trials (RCTs) published before August 8, 2023. All identified studies were screened following the selection criteria. Finally, we employed the STATA 14.0 software for conducting a <em>meta</em>-analysis to evaluate the efficacy and safety of ESWT.</p></div><div><h3>Results</h3><p>A total of ten RCTs with moderate methodological quality were included for data analysis. The findings showed that ESWT was significantly associated with significantly complete healed ulcers (risk ratio [RR]: 1.57, 95 % confidence interval [CI]:1.26 to 1.95) and lower rate of unchanged ulcers (RR: 0.25, 95 %CI: 0.14 to 0.42) compared to controls. Subgroup analysis further revealed that ESWT was better than both hyperbaric oxygen therapy (HOT) and the standard of care (SOC). Moreover, ESWT also significantly improved the average transcutaneous partial oxygen pressure (TcPO2) (mean difference[MD]: 1.71, 95 %CI: 1.22 to 2.19, p &lt; 0.001). However, the rate of ≥ 50 % improved ulcers and treatment-emergent adverse events (TEAEs) were not significantly different between the ESWT and controls.</p></div><div><h3>Conclusions</h3><p>ESWT has shown promising efficacy and a favorable safety profile in the treatment of DFUs.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucose levels at hospital admission are associated with 5 year mortality 入院时的血糖水平与 5 年死亡率有关。
IF 6.1 3区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-30 DOI: 10.1016/j.diabres.2024.111840

Aim

We aimed to determine if hospital admission hyperglycaemia and hypoglycaemia are associated with increased long-term mortality.

Methods

A post-hoc analysis of data from a trial of glucose screening in the emergency department was conducted. Data were linked with a death registry up to 5 years after admission. The relationship between admission glucose and mortality was examined by cox regression. Further analyses of people who survived the admission and subsequent 28 days was performed.

Results

There were 131,322 patients, of whom 38,712 (29.5 %) died. Mean follow-up was 3·3 ± 1·5 years. Compared to the reference glucose band of 6·1-8·0 mmol/L, there was increased mortality in higher bands, reaching a hazard ratio (HR) of 1·44 (95 %CI 1·34-1·55, p < 0·001) for people with glucose > 20·0 mmol/L. The HR was 1·56 (95 %CI 1·46-1·68, p < 0·001) for people with glucose ≤ 4·0 mmol/L. Similar relationships were observed among 28-day survivors. The relationships were attenuated among people with known diabetes.

Among 4867 subjects with glucose ≥ 14·0 mmol/L, those diagnosed with diabetes during the admission had lower mortality compared to subjects where the diagnosis was not made (HR 0·53, 95 %CI 0·40-0·72, p < 0·001). This was attenuated among 28-day survivors.

Conclusion

Hyperglycaemia and hypoglycaemia on hospital admission are associated with increased long-term mortality.

目的:我们旨在确定入院高血糖和低血糖是否与长期死亡率增加有关:我们对急诊科血糖筛查试验的数据进行了事后分析。数据与入院后 5 年内的死亡登记相联系。入院血糖与死亡率之间的关系通过 Cox 回归进行了检验。此外,还对入院后 28 天内的存活者进行了进一步分析:共有 131,322 名患者,其中 38,712 人(29.5%)死亡。平均随访时间为 3-3 ± 1-5 年。与 6-1-8-0 mmol/L 的参考血糖带相比,血糖带越高,死亡率越高,危险比(HR)为 1-44 (95 %CI 1-34-1-55, p 20-0 mmol/L)。HR为1-56(95 %CI 1-46-1-68,p 结论:入院时的高血糖和低血糖与长期死亡率增加有关。
{"title":"Glucose levels at hospital admission are associated with 5 year mortality","authors":"","doi":"10.1016/j.diabres.2024.111840","DOIUrl":"10.1016/j.diabres.2024.111840","url":null,"abstract":"<div><h3>Aim</h3><p>We aimed to determine if hospital admission hyperglycaemia and hypoglycaemia are associated with increased long-term mortality.</p></div><div><h3>Methods</h3><p>A post-hoc analysis of data from a trial of glucose screening in the emergency department was conducted. Data were linked with a death registry up to 5 years after admission. The relationship between admission glucose and mortality was examined by cox regression. Further analyses of people who survived the admission and subsequent 28 days was performed.</p></div><div><h3>Results</h3><p>There were 131,322 patients, of whom 38,712 (29.5 %) died. Mean follow-up was 3·3 ± 1·5 years. Compared to the reference glucose band of 6·1-8·0 mmol/L, there was increased mortality in higher bands, reaching a hazard ratio (HR) of 1·44 (95 %CI 1·34-1·55, p &lt; 0·001) for people with glucose &gt; 20·0 mmol/L. The HR was 1·56 (95 %CI 1·46-1·68, p &lt; 0·001) for people with glucose ≤ 4·0 mmol/L. Similar relationships were observed among 28-day survivors. The relationships were attenuated among people with known diabetes.</p><p>Among 4867 subjects with glucose ≥ 14·0 mmol/L, those diagnosed with diabetes during the admission had lower mortality compared to subjects where the diagnosis was not made (HR 0·53, 95 %CI 0·40-0·72, p &lt; 0·001). This was attenuated among 28-day survivors.</p></div><div><h3>Conclusion</h3><p>Hyperglycaemia and hypoglycaemia on hospital admission are associated with increased long-term mortality.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
International Diabetes Federation granted special consultative status with UN ECOSOC 国际糖尿病联合会获得联合国经社理事会特别咨商地位。
IF 6.1 3区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-28 DOI: 10.1016/j.diabres.2024.111842
{"title":"International Diabetes Federation granted special consultative status with UN ECOSOC","authors":"","doi":"10.1016/j.diabres.2024.111842","DOIUrl":"10.1016/j.diabres.2024.111842","url":null,"abstract":"","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between changes in glycosylated hemoglobin during the second and third trimesters and adverse pregnancy outcomes among women without hyperglycemia in pregnancy 怀孕第二和第三个月期间糖化血红蛋白的变化与妊娠期无高血糖妇女的不良妊娠结局之间的关系
IF 6.1 3区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-28 DOI: 10.1016/j.diabres.2024.111841

Objective

To explore the relationship between changes in glycated hemoglobin (HbA1c) during the second and third trimesters and adverse pregnancy outcomes among women without hyperglycemia in pregnancy (HIP).

Research design and methods: A total of 1,057 pregnant women who underwent serum HbA1c and delivered at Women’s Hospital, Zhejiang University School of Medicine from May 2022 to March 2023, were included in this study. They were divided into four groups. Associations were evaluated using multivariate logistic regression analysis.

Results

In our study, an upward trend in HbA1c levels in the second trimester (HbA1c_S) and third trimester (HbA1c_T) among women without HIP was demonstrated. Multivariate logistics regression analysis showed significant associations: Pregnant women with HbA1c_S<5.5 %, HbA1c_T≥6.1 %, or with HbA1c_S≥5.5 %, HbA1c_T<6.1 % had a significant correlation with hypertensive disorders of pregnancy (HDP) (aOR:2.72, 95 %CI=1.24–5.97;aOR:2.59, 95 %CI=1.15–5.84). Furthermore, for each 1 % increase in the difference value of HbA1c between the second and third trimesters, the risk of HDP increased about 1.96 times, and the risk of delivering a large-for-gestational-age baby increased about 1.30 times.

Conclusion

Among pregnant women without HIP, elevated HbA1c levels in the second or third trimester are associated with increased risks of adverse pregnancy outcomes.

目的 探讨无妊娠期高血糖(HIP)的孕妇第二和第三个孕期糖化血红蛋白(HbA1c)的变化与不良妊娠结局之间的关系:本研究纳入了2022年5月至2023年3月期间在浙江大学医学院附属女子医院接受血清HbA1c检查并分娩的1057名孕妇。她们被分为四组。结果 在我们的研究中,未患 HIP 的产妇在第二孕期(HbA1c_S)和第三孕期(HbA1c_T)的 HbA1c 水平呈上升趋势。多变量物流回归分析显示两者之间存在显著关联:HbA1c_S<5.5 %、HbA1c_T≥6.1 %或 HbA1c_S≥5.5 %、HbA1c_T<6.1 %的孕妇与妊娠高血压疾病(HDP)有显著相关性(aOR:2.72, 95 %CI=1.24-5.97;aOR:2.59, 95 %CI=1.15-5.84)。此外,在第二和第三孕期,HbA1c 的差值每增加 1%,发生 HDP 的风险就会增加约 1.96 倍,而分娩巨大胎儿的风险则会增加约 1.30 倍。
{"title":"Association between changes in glycosylated hemoglobin during the second and third trimesters and adverse pregnancy outcomes among women without hyperglycemia in pregnancy","authors":"","doi":"10.1016/j.diabres.2024.111841","DOIUrl":"10.1016/j.diabres.2024.111841","url":null,"abstract":"<div><h3>Objective</h3><p>To explore the relationship between changes in glycated hemoglobin (HbA1c) during the second and third trimesters and adverse pregnancy outcomes among women without hyperglycemia in pregnancy (HIP).</p><p>Research design and methods: A total of 1,057 pregnant women who underwent serum HbA1c and delivered at Women’s Hospital, Zhejiang University School of Medicine from May 2022 to March 2023, were included in this study. They were divided into four groups. Associations were evaluated using multivariate logistic regression analysis.</p></div><div><h3>Results</h3><p>In our study, an upward trend in HbA1c levels in the second trimester (HbA1c_S) and third trimester (HbA1c_T) among women without HIP was demonstrated. Multivariate logistics regression analysis showed significant associations: Pregnant women with HbA1c_S&lt;5.5 %, HbA1c_T≥6.1 %, or with HbA1c_S≥5.5 %, HbA1c_T&lt;6.1 % had a significant correlation with hypertensive disorders of pregnancy (HDP) (aOR:2.72, 95 %CI=1.24–5.97;aOR:2.59, 95 %CI=1.15–5.84). Furthermore, for each 1 % increase in the difference value of HbA1c between the second and third trimesters, the risk of HDP increased about 1.96 times, and the risk of delivering a large-for-gestational-age baby increased about 1.30 times.</p></div><div><h3>Conclusion</h3><p>Among pregnant women without HIP, elevated HbA1c levels in the second or third trimester are associated with increased risks of adverse pregnancy outcomes.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice 在临床实践中,三重跨膜调节剂疗法对囊性纤维化相关糖尿病患者糖代谢的影响。
IF 6.1 3区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-24 DOI: 10.1016/j.diabres.2024.111839

Aims

To evaluate the impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on Cystic Fibrosis Related Diabetes (CFRD) glycemic control and insulin treatment in patients with CFRD during clinical practice.

Methods

We carried out a retrospective observational study of 23 adult patients with CFRD who started treatment with ETI. They had, at least, one F508del mutation. Data were collected before ETI initiation and 3, 6, and 12 months after.

Results

Glycemic control measured by HbA1c significantly improved by 0.3 % (0.1–0.5) after 3 months of ETI therapy (p = 0.004) and kept this improvement during follow-up (p < 0.001). The proportion of patients needing multiple daily injections of insulin was reduced by 16 % (p = 0.023). Total daily insulin dose dropped by 0.12 (0.05–0.18) UI/kg/day (p < 0.001). Data derived from Flash Continuous Glucose Monitoring (CGM) for patients treated with insulin stayed unchanged after insulin reduction, except for a significant 8 % (0.3–15.6) increase in the Time In Tight Range (TITR) between 70 and 140 mg/dL (p = 0.043).

Conclusion

ETI therapy impacted CFRD in clinical practice reducing insulin needs and improving glycemic control measured by HbA1c and CGM. The improvements can be observed from the first 3 months of treatment.

目的:评估 Elexacaftor/tezacaftor/ivacaftor (ETI) 疗法在临床实践中对囊性纤维化相关糖尿病(CFRD)患者血糖控制和胰岛素治疗的影响 方法:我们对 23 名开始接受 ETI 治疗的囊性纤维化相关糖尿病(CFRD)成年患者进行了回顾性观察研究。他们至少有一个 F508del 基因突变。研究收集了开始使用 ETI 之前以及之后 3、6 和 12 个月的数据:结果:接受 ETI 治疗 3 个月后,通过 HbA1c 测定的血糖控制明显改善了 0.3 % (0.1-0.5)(p = 0.004),并在随访期间保持了这种改善(p 结论:ETI 治疗对 CFRD 的临床表现产生了影响:在临床实践中,ETI疗法对CFRD产生了影响,减少了胰岛素需求,改善了通过HbA1c和CGM测量的血糖控制。从治疗的前 3 个月就可以观察到这种改善。
{"title":"Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice","authors":"","doi":"10.1016/j.diabres.2024.111839","DOIUrl":"10.1016/j.diabres.2024.111839","url":null,"abstract":"<div><h3>Aims</h3><p>To evaluate the impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on Cystic Fibrosis Related Diabetes (CFRD) glycemic control and insulin treatment in patients with CFRD during clinical practice.</p></div><div><h3>Methods</h3><p>We carried out a retrospective observational study of 23 adult patients with CFRD who started treatment with ETI. They had, at least, one F508del mutation. Data were collected before ETI initiation and 3, 6, and 12 months after.</p></div><div><h3>Results</h3><p>Glycemic control measured by HbA1c significantly improved by 0.3 % (0.1–0.5) after 3 months of ETI therapy (p = 0.004) and kept this improvement during follow-up (p &lt; 0.001). The proportion of patients needing multiple daily injections of insulin was reduced by 16 % (p = 0.023). Total daily insulin dose dropped by 0.12 (0.05–0.18) UI/kg/day (p &lt; 0.001). Data derived from Flash Continuous Glucose Monitoring (CGM) for patients treated with insulin stayed unchanged after insulin reduction, except for a significant 8 % (0.3–15.6) increase in the Time In Tight Range (TITR) between 70 and 140 mg/dL (p = 0.043).</p></div><div><h3>Conclusion</h3><p>ETI therapy impacted CFRD in clinical practice reducing insulin needs and improving glycemic control measured by HbA1c and CGM. The improvements can be observed from the first 3 months of treatment.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142072328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serious digital games for diabetes Mellitus: A scoping review of its current State, Accessibility, and functionality for patients and healthcare providers 治疗糖尿病的严肃数字游戏:对其现状、可访问性以及为患者和医疗服务提供者提供的功能进行范围审查。
IF 6.1 3区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-22 DOI: 10.1016/j.diabres.2024.111833

The global rise in diabetes prevalence poses a significant challenge to healthcare providers, stimulating interest in digital interventions such as educational games. However, the impact and availability of research-developed diabetes games remain uncertain. This scoping review aimed to provide a comprehensive overview of serious games for diabetes, encompassing their availability, characteristics and health effects. Through an electronic search in multiple databases, a total of 21 articles addressing 23 games were included in the literature review. The majority of these games were inaccessible outside of research settings, despite demonstrating positive effects on various aspects of diabetes management, including knowledge, physical activity, self-management, mental well-being, and HbA1c levels. Most games were designed for mobile phones, targeting both children and adults. A subsequent app store search revealed 13 additional diabetes games, however nearly none (7.7%) of these underwent research scrutiny, leaving their expected effects uncertain. The disparity between evidence-based games and those available in app stores underscores the need for bridging this gap to ensure the availability of effective digital games for diabetes management worldwide.

全球糖尿病发病率的上升给医疗保健提供者带来了巨大挑战,激发了人们对教育游戏等数字干预措施的兴趣。然而,研究开发的糖尿病游戏的影响和可用性仍不确定。本范围界定综述旨在全面概述糖尿病严肃游戏,包括其可用性、特点和对健康的影响。通过在多个数据库中进行电子检索,共有 21 篇涉及 23 款游戏的文章被纳入文献综述。尽管这些游戏对糖尿病管理的各个方面(包括知识、体育锻炼、自我管理、心理健康和 HbA1c 水平)产生了积极影响,但大多数游戏在研究环境之外无法获得。大多数游戏都是为手机设计的,针对儿童和成人。在随后的应用商店搜索中又发现了 13 款糖尿病游戏,但其中几乎没有一款(7.7%)经过研究审查,因此其预期效果并不确定。以证据为基础的游戏与应用商店中的游戏之间的差距凸显了弥合这一差距的必要性,以确保在全球范围内提供用于糖尿病管理的有效数字游戏。
{"title":"Serious digital games for diabetes Mellitus: A scoping review of its current State, Accessibility, and functionality for patients and healthcare providers","authors":"","doi":"10.1016/j.diabres.2024.111833","DOIUrl":"10.1016/j.diabres.2024.111833","url":null,"abstract":"<div><p>The global rise in diabetes prevalence poses a significant challenge to healthcare providers, stimulating interest in digital interventions such as educational games. However, the impact and availability of research-developed diabetes games remain uncertain. This scoping review aimed to provide a comprehensive overview of serious games for diabetes, encompassing their availability, characteristics and health effects. Through an electronic search in multiple databases, a total of 21 articles addressing 23 games were included in the literature review. The majority of these games were inaccessible outside of research settings, despite demonstrating positive effects on various aspects of diabetes management, including knowledge, physical activity, self-management, mental well-being, and HbA1c levels. Most games were designed for mobile phones, targeting both children and adults. A subsequent app store search revealed 13 additional diabetes games, however nearly none (7.7%) of these underwent research scrutiny, leaving their expected effects uncertain. The disparity between evidence-based games and those available in app stores underscores the need for bridging this gap to ensure the availability of effective digital games for diabetes management worldwide.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0168822724007435/pdfft?md5=7c7a406cb1bad49c21d13398410242fa&pid=1-s2.0-S0168822724007435-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Excellence in the management of Advanced Hybrid Closed-Loop Systems: Lessons from the Polish cohort 先进混合闭环系统的卓越管理:波兰的经验教训。
IF 6.1 3区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-22 DOI: 10.1016/j.diabres.2024.111832

Background

The aim of the study was to analyze the real-world performance of MiniMed 780G (MM780G) Advanced Hybrid Closed Loop (AHCL) system users from Poland (PL) and compare it to the European region excluding Poland (EU-PL) in order to identify factors contributing to potential differences. The former achieved some of the best Time in Range (TIR) results globally using this technology.

Methods

CareLink Personal data uploaded by MM780G system users from August 2020 to December 2022 were analyzed.

Results

The Polish users (N=1304) on average reached to TIR of 79.1 ± 8.7 % (vs 73.0 ± 10.0 % for EU-PL, N=55659), a TBR<54 mg/dL of 0.6 ± 0.7 % (vs 0.4 ± 0.6 %) and a TBR<70 mg/dL of 2.9 ± 2.1 % (vs 2.1 ± 1.8 %). The adoption rate of optimal settings (i.e, GT=100 mg/dL, AIT=2hr) in PL was high (19.7 % vs 6.3 %), and filtering on optimal setting users led to less pronounced differences in glycemic control between PL and EU-PL. A univariable analysis with post-AHCL TIR showed that geography itself (PL vs EU-PL) is not a significant contributor to a high post-AHCL TIR (p = 0.15), and that much of the Polish post-AHCL TIR can be explained by the high pre-AHCL TIR.

Conclusion

The Polish MM780G users achieved better glycemic control than the general European population (excluding Poland). This is largely attributable to the adoption of optimal settings in Poland and the already high glycemic outcomes at system start. As these characteristics can be implemented elsewhere, we believe this outstanding result can be obtained in other countries as well.

研究背景本研究旨在分析波兰(PL)MiniMed 780G(MM780G)高级混合闭环(AHCL)系统用户的实际表现,并与除波兰以外的欧洲地区(EU-PL)进行比较,以找出造成潜在差异的因素。前者使用该技术在全球范围内取得了最佳范围内时间(TIR)结果:方法:分析 MM780G 系统用户在 2020 年 8 月至 2022 年 12 月期间上传的 CareLink 个人数据:结果:波兰用户(N=1304)的平均 TIR 为 79.1 ± 8.7 %(欧盟-波兰为 73.0 ± 10.0 %,N=55659),TBRC 结论:波兰 MM780G 用户的平均 TIR 为 79.1 ± 8.7 %(欧盟-波兰为 73.0 ± 10.0 %,N=55659):波兰 MM780G 用户的血糖控制情况优于欧洲一般人群(不包括波兰)。这在很大程度上归功于波兰采用了最佳设置,以及在系统启动时已经取得了较高的血糖结果。由于这些特点可以在其他地方实施,我们相信其他国家也能取得这一优异成绩。
{"title":"Excellence in the management of Advanced Hybrid Closed-Loop Systems: Lessons from the Polish cohort","authors":"","doi":"10.1016/j.diabres.2024.111832","DOIUrl":"10.1016/j.diabres.2024.111832","url":null,"abstract":"<div><h3>Background</h3><p>The aim of the study was to analyze the real-world performance of MiniMed 780G (MM780G) Advanced Hybrid Closed Loop (AHCL) system users from Poland (PL) and compare it to the European region excluding Poland (EU-PL) in order to identify factors contributing to potential differences. The former achieved some of the best Time in Range (TIR) results globally using this technology.</p></div><div><h3>Methods</h3><p>CareLink Personal data uploaded by MM780G system users from August 2020 to December 2022 were analyzed<strong>.</strong></p></div><div><h3>Results</h3><p>The Polish users (N=1304) on average reached to TIR of 79.1 ± 8.7 % (vs 73.0 ± 10.0 % for EU-PL, N=55659), a TBR&lt;54 mg/dL of 0.6 ± 0.7 % (vs 0.4 ± 0.6 %) and a TBR&lt;70 mg/dL of 2.9 ± 2.1 % (vs 2.1 ± 1.8 %). The adoption rate of optimal settings (i.e, GT=100 mg/dL, AIT=2hr) in PL was high (19.7 % vs 6.3 %), and filtering on optimal setting users led to less pronounced differences in glycemic control between PL and EU-PL. A univariable analysis with post-AHCL TIR showed that geography itself (PL vs EU-PL) is not a significant contributor to a high post-AHCL TIR (p = 0.15), and that much of the Polish post-AHCL TIR can be explained by the high pre-AHCL TIR.</p></div><div><h3>Conclusion</h3><p>The Polish MM780G users achieved better glycemic control than the general European population (excluding Poland). This is largely attributable to the adoption of optimal settings in Poland and the already high glycemic outcomes at system start. As these characteristics can be implemented elsewhere, we believe this outstanding result can be obtained in other countries as well.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0168822724007423/pdfft?md5=68c1ce921e597f02849f34399c99e5b6&pid=1-s2.0-S0168822724007423-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The causal relationship between 91 inflammatory cytokines and Gestational Diabetes Mmellitus: A bidirectional two-sample Mendelian randomization study 91 种炎症细胞因子与妊娠糖尿病之间的因果关系:双向双样本孟德尔随机研究
IF 6.1 3区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-22 DOI: 10.1016/j.diabres.2024.111838

Background

Gestational Diabetes Mellitus (GDM) poses significant risks to maternal and fetal health, yet its precise etiology remains unclear. Observational studies have demonstrated a link between specific inflammatory cytokines and the occurrence of GDM, but the causal relationships remain uncertain.

Methods

Utilizing publicly accessible genetic data, we performed a bidirectional two-sample mendelian randomization (MR) analysis to elucidate the causal association between 91 inflammatory cytokines and GDM. Sensitivity analysis was carried out to evaluate the robustness, heterogeneity, and potential presence of horizontal pleiotropy within the results.

Results

Elevated levels of Interleukin-7 (IL7) and Neurturin (NRTN) (OR=1.104, 95 % CI=1.003–1.216, p = 0.042; OR=1.102, 95 % CI=1.023–1.187, p = 0.010), along with decreased levels of Glial cell line-derived neurotrophic factor (GDNF), Interleukin-12 subunit beta (IL12β), and Interleukin-20 (IL20) (OR=0.911, 95 % CI=0.849–0.979, p = 0.010;OR=0.955, 95 % CI=0.916–0.996, p = 0.033; OR=0.892, 95 % CI=0.819–0.971, p = 0.008), are associated with increased GDM risk. Additionally, GDM occurrence correlates with increased Matrix metalloproteinase-10 (MMP-10) and decreased Interleukin-20 receptor subunit alpha (IL-20Rα) levels (OR=1.042, 95 % CI=1.002–1.084, p = 0.038; OR=0.949, 95 % CI=0.909–0.992, p = 0.021). Sensitivity analyses detected no significant heterogeneity or pleiotropy.

Conclusion

This study has clarified the causal link between inflammatory cytokines and GDM, thereby enhancing our comprehension of the potential mechanisms involved in GDM pathogenesis. These findings offer new insights into the etiology, diagnosis, and therapeutic strategies for GDM.

背景妊娠糖尿病(GDM)对母体和胎儿的健康构成重大风险,但其确切的病因仍不清楚。观察性研究表明,特定的炎性细胞因子与 GDM 的发生有关,但其因果关系仍不确定。方法利用公开的遗传数据,我们进行了双向双样本泯灭随机化(MR)分析,以阐明 91 种炎性细胞因子与 GDM 之间的因果关系。结果白细胞介素-7(IL7)和神经营养素(NRTN)水平升高(OR=1.104,95 % CI=1.003-1.216,p = 0.042;OR=1.102,95 % CI=1.023-1.187,p = 0.010),以及胶质细胞系源性神经营养因子(GDNF)、白细胞介素-12亚基β(IL12β)和白细胞介素-20(IL20)水平的降低(OR=0.911,95 % CI=0.849-0.979,p = 0.010;OR=0.955,95 % CI=0.916-0.996,p = 0.033;OR=0.892,95 % CI=0.819-0.971,p = 0.008)与 GDM 风险增加有关。此外,GDM 的发生与基质金属蛋白酶-10(MMP-10)水平升高和白细胞介素-20 受体亚基α(IL-20Rα)水平降低有关(OR=1.042,95 % CI=1.002-1.084,p = 0.038;OR=0.949,95 % CI=0.909-0.992,p = 0.021)。该研究阐明了炎性细胞因子与 GDM 之间的因果关系,从而加深了我们对 GDM 发病机制的理解。这些发现为 GDM 的病因学、诊断和治疗策略提供了新的见解。
{"title":"The causal relationship between 91 inflammatory cytokines and Gestational Diabetes Mmellitus: A bidirectional two-sample Mendelian randomization study","authors":"","doi":"10.1016/j.diabres.2024.111838","DOIUrl":"10.1016/j.diabres.2024.111838","url":null,"abstract":"<div><h3>Background</h3><p>Gestational Diabetes Mellitus (GDM) poses significant risks to maternal and fetal health, yet its precise etiology remains unclear. Observational studies have demonstrated a link between specific inflammatory cytokines and the occurrence of GDM, but the causal relationships remain uncertain.</p></div><div><h3>Methods</h3><p>Utilizing publicly accessible genetic data, we performed a bidirectional two-sample mendelian randomization (MR) analysis to elucidate the causal association between 91 inflammatory cytokines and GDM. Sensitivity analysis was carried out to evaluate the robustness, heterogeneity, and potential presence of horizontal pleiotropy within the results.</p></div><div><h3>Results</h3><p>Elevated levels of Interleukin-7 (IL7) and Neurturin (NRTN) (OR=1.104, 95 % CI=1.003–1.216, <em>p</em> = 0.042; OR=1.102, 95 % CI=1.023–1.187, <em>p</em> = 0.010), along with decreased levels of Glial cell line-derived neurotrophic factor (GDNF), Interleukin-12 subunit beta (IL12β), and Interleukin-20 (IL20) (OR=0.911, 95 % CI=0.849–0.979, <em>p</em> = 0.010;OR=0.955, 95 % CI=0.916–0.996, <em>p</em> = 0.033; OR=0.892, 95 % CI=0.819–0.971, <em>p</em> = 0.008), are associated with increased GDM risk. Additionally, GDM occurrence correlates with increased Matrix metalloproteinase-10 (MMP-10) and decreased Interleukin-20 receptor subunit alpha (IL-20Rα) levels (OR=1.042, 95 % CI=1.002–1.084, <em>p</em> = 0.038; OR=0.949, 95 % CI=0.909–0.992, <em>p</em> = 0.021). Sensitivity analyses detected no significant heterogeneity or pleiotropy.</p></div><div><h3>Conclusion</h3><p>This study has clarified the causal link between inflammatory cytokines and GDM, thereby enhancing our comprehension of the potential mechanisms involved in GDM pathogenesis. These findings offer new insights into the etiology, diagnosis, and therapeutic strategies for GDM.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142048033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nationwide prevalence of type 2 diabetes mellitus and pre-diabetes in Pakistan: A systematic review and meta-analysis 巴基斯坦全国 2 型糖尿病和糖尿病前期的患病率:系统回顾和荟萃分析。
IF 6.1 3区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-22 DOI: 10.1016/j.diabres.2024.111815

Type 2 diabetes mellitus (T2DM) and pre-diabetes (pre-DM) are significant health concerns in Pakistan. This systematic review and meta-analysis estimate the prevalence of T2DM and pre-DM, assessing regional, gender, and urban–rural differences. We searched PubMed, Scopus, Cochrane, and PakMediNet databases, identifying 3478 articles. After screening, 17 studies from 1995 to 2018 were included. The pooled prevalence of T2DM and pre-DM in Pakistan was found to be 10.0 % and 11.0 %, respectively. This equates to approximately 24 million individuals with T2DM and 26 million with pre-DM, totaling 50 million affected. Rural areas showed higher T2DM prevalence post-2000, with an odds ratio (OR) of 1.25 (95 % CI: 0.73 to 2.14). Gender analysis revealed a slightly higher, though statistically insignificant, prevalence of T2DM in females and a significantly higher prevalence of pre-DM in males (OR: 0.79, 95 % CI: 0.63 to 0.98). Regionally, Punjab had the highest T2DM prevalence (16 %), followed by Baluchistan (15 %), Sindh (14 %), and Khyber Pakhtunkhwa (KPK) (11 %). There is a substantial burden of T2DM and pre-DM in Pakistan, with significant regional and gender differences. Targeted interventions and resource allocation are needed to address the rising prevalence of diabetes, focusing on early detection and lifestyle modifications.

2 型糖尿病(T2DM)和糖尿病前期(Pre-DM)是巴基斯坦的重大健康问题。本系统综述和荟萃分析估计了 T2DM 和糖尿病前期的发病率,评估了地区、性别和城乡差异。我们检索了 PubMed、Scopus、Cochrane 和 PakMediNet 数据库,共发现 3478 篇文章。经过筛选,纳入了 1995 年至 2018 年的 17 项研究。研究发现,巴基斯坦 T2DM 和 DM 前期的总患病率分别为 10.0% 和 11.0%。这相当于约有 2400 万 T2DM 患者和 2600 万 DM 前期患者,总计 5000 万患者。2000 年后,农村地区的 T2DM 患病率较高,几率比 (OR) 为 1.25(95 % CI:0.73 至 2.14)。性别分析显示,女性的 T2DM 患病率略高,但在统计上并不显著,而男性的糖尿病前期患病率则明显较高(OR:0.79,95 % CI:0.63 至 0.98)。从地区来看,旁遮普省的 T2DM 患病率最高(16%),其次是俾路支省(15%)、信德省(14%)和开伯尔-普赫图赫瓦省(11%)。在巴基斯坦,T2DM 和 DM 前期患者人数众多,地区和性别差异显著。需要采取有针对性的干预措施并分配资源,以解决糖尿病患病率不断上升的问题,重点是早期发现和改变生活方式。
{"title":"Nationwide prevalence of type 2 diabetes mellitus and pre-diabetes in Pakistan: A systematic review and meta-analysis","authors":"","doi":"10.1016/j.diabres.2024.111815","DOIUrl":"10.1016/j.diabres.2024.111815","url":null,"abstract":"<div><p>Type 2 diabetes mellitus (T2DM) and pre-diabetes (pre-DM) are significant health concerns in Pakistan. This systematic review and <em>meta</em>-analysis estimate the prevalence of T2DM and pre-DM, assessing regional, gender, and urban–rural differences. We searched PubMed, Scopus, Cochrane, and PakMediNet databases, identifying 3478 articles. After screening, 17 studies from 1995 to 2018 were included. The pooled prevalence of T2DM and pre-DM in Pakistan was found to be 10.0 % and 11.0 %, respectively. This equates to approximately 24 million individuals with T2DM and 26 million with pre-DM, totaling 50 million affected. Rural areas showed higher T2DM prevalence post-2000, with an odds ratio (OR) of 1.25 (95 % CI: 0.73 to 2.14). Gender analysis revealed a slightly higher, though statistically insignificant, prevalence of T2DM in females and a significantly higher prevalence of pre-DM in males (OR: 0.79, 95 % CI: 0.63 to 0.98). Regionally, Punjab had the highest T2DM prevalence (16 %), followed by Baluchistan (15 %), Sindh (14 %), and Khyber Pakhtunkhwa (KPK) (11 %). There is a substantial burden of T2DM and pre-DM in Pakistan, with significant regional and gender differences. Targeted interventions and resource allocation are needed to address the rising prevalence of diabetes, focusing on early detection and lifestyle modifications.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The interplay of extracellular vesicles in the pathogenesis of metabolic impairment and type 2 diabetes 细胞外囊泡在代谢损伤和 2 型糖尿病发病机制中的相互作用。
IF 6.1 3区 医学 Q1 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-21 DOI: 10.1016/j.diabres.2024.111837

The pathogenesis of type 2 diabetes (T2D) involves dysfunction in multiple organs, including the liver, muscle, adipose tissue, and pancreas, leading to insulin resistance and β cell failure. Recent studies highlight the significant role of extracellular vesicles (EVs) in mediating inter-organ communication in T2D. This review investigates the role of EVs, focusing on their presence and biological significance in human plasma and tissues affected by T2D. We explore specific EV cargo, such as miRNAs and proteins, which affect insulin signaling and glucose metabolism, emphasizing their potential as biomarkers. By highlighting the diagnostic and therapeutic potential of EVs, we aim to provide new insights into their role in early detection, disease monitoring, and innovative treatment strategies for T2D.

2 型糖尿病(T2D)的发病机制涉及多个器官的功能障碍,包括肝脏、肌肉、脂肪组织和胰腺,从而导致胰岛素抵抗和 β 细胞衰竭。最近的研究强调了细胞外囊泡 (EVs) 在 T2D 中介导器官间沟通的重要作用。本综述探讨了 EVs 的作用,重点是它们在受 T2D 影响的人体血浆和组织中的存在及其生物学意义。我们探讨了影响胰岛素信号传导和葡萄糖代谢的特定 EV 载体,如 miRNA 和蛋白质,强调了它们作为生物标记物的潜力。通过强调 EVs 在诊断和治疗方面的潜力,我们希望就 EVs 在 T2D 早期检测、疾病监测和创新治疗策略方面的作用提供新的见解。
{"title":"The interplay of extracellular vesicles in the pathogenesis of metabolic impairment and type 2 diabetes","authors":"","doi":"10.1016/j.diabres.2024.111837","DOIUrl":"10.1016/j.diabres.2024.111837","url":null,"abstract":"<div><p>The pathogenesis of type 2 diabetes (T2D) involves dysfunction in multiple organs, including the liver, muscle, adipose tissue, and pancreas, leading to insulin resistance and β cell failure. Recent studies highlight the significant role of extracellular vesicles (EVs) in mediating inter-organ communication in T2D. This review investigates the role of EVs, focusing on their presence and biological significance in human plasma and tissues affected by T2D. We explore specific EV cargo, such as miRNAs and proteins, which affect insulin signaling and glucose metabolism, emphasizing their potential as biomarkers. By highlighting the diagnostic and therapeutic potential of EVs, we aim to provide new insights into their role in early detection, disease monitoring, and innovative treatment strategies for T2D.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":null,"pages":null},"PeriodicalIF":6.1,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Diabetes research and clinical practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1